Search Results for: TP53

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel ABL1 ABL proto-oncogene 1, non-receptor tyrosine kinase
  • Regulation of actin dynamics for phagocytic cup formation
  • Role of ABL in ROBO-SLIT signaling
  • Role of ABL in ROBO-SLIT signaling
  • Myogenesis
  • Myogenesis
  • RHO GTPases Activate WASPs and WAVEs
  • HDR through Single Strand Annealing (SSA)
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Cyclin D associated events in G1
  • RUNX1 regulates transcription of genes involved in differentiation of HSCs
  • RUNX2 regulates osteoblast differentiation
  • FCGR3A-mediated phagocytosis
  • Factors involved in megakaryocyte development and platelet production
  • MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
  • Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells
  • ATP
  • Imatinib
  • Dasatinib
  • N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide
  • Nilotinib
  • XL228
  • Bosutinib
  • 2-{[(6-OXO-1,6-DIHYDROPYRIDIN-3-YL)METHYL]AMINO}-N-[4-PROPYL-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
  • 1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA
  • Myristic acid
  • PD-166326
  • 5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE
  • 2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide
  • Regorafenib
  • Ponatinib
  • Fostamatinib
  • Brigatinib
  • Radotinib
  • Asciminib
  • Umbralisib
  • Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
  • Chronic myeloid leukemia (CML)
Novel ACKR3 atypical chemokine receptor 3
  • Chemokine receptors bind chemokines
  • G alpha (i) signalling events
Novel ACTA1 actin alpha 1, skeletal muscle
  • Striated Muscle Contraction
  • Regulation of CDH1 Function
  • Formation of the dystrophin-glycoprotein complex (DGC)
  • Formation of the dystrophin-glycoprotein complex (DGC)
  • Latrunculin A
  • Sucrose
  • Ulapualide A
  • Kabiramide C
  • Jaspisamide A
  • Tmr
  • 1-Methylhistidine
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Aplyronine A
  • Reidispongiolide A
  • Reidispongiolide C
  • Sphinxolide B
  • Latrunculin B
  • Cap myopathy
  • Congenital fiber type disproportion (CFTD)
  • Nemaline myopathy
Novel AGT angiotensinogen
  • PPARA activates gene expression
  • Metabolism of Angiotensinogen to Angiotensins
  • Metabolism of Angiotensinogen to Angiotensins
  • Peptide ligand-binding receptors
  • Peptide ligand-binding receptors
  • G alpha (q) signalling events
  • G alpha (i) signalling events
  • Zinc
  • Copper
  • Sparsentan
  • Zinc acetate
  • Renal tubular dysgenesis
Novel AKAP5 A-kinase anchoring protein 5
  • Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
  • Trafficking of AMPA receptors
  • ROBO receptors bind AKAP5
  • ROBO receptors bind AKAP5
Novel AKT1 AKT serine/threonine kinase 1
  • Activation of BAD and translocation to mitochondria
  • PIP3 activates AKT signaling
  • PIP3 activates AKT signaling
  • Downregulation of ERBB2:ERBB3 signaling
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • MTOR signalling
  • AKT phosphorylates targets in the cytosol
  • AKT phosphorylates targets in the cytosol
  • AKT phosphorylates targets in the nucleus
  • Negative regulation of the PI3K/AKT network
  • eNOS activation
  • AKT-mediated inactivation of FOXO1A
  • Integrin signaling
  • Deactivation of the beta-catenin transactivating complex
  • CD28 dependent PI3K/Akt signaling
  • Co-inhibition by CTLA4
  • G beta:gamma signalling through PI3Kgamma
  • Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA
  • KSRP (KHSRP) binds and destabilizes mRNA
  • VEGFR2 mediated vascular permeability
  • TP53 Regulates Metabolic Genes
  • Constitutive Signaling by AKT1 E17K in Cancer
  • Interleukin-4 and Interleukin-13 signaling
  • Regulation of TP53 Degradation
  • Regulation of TP53 Activity through Acetylation
  • Regulation of TP53 Activity through Association with Co-factors
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Cyclin E associated events during G1/S transition
  • Cyclin A:Cdk2-associated events at S phase entry
  • PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1
  • RAB GEFs exchange GTP for GDP on RABs
  • RUNX2 regulates genes involved in cell migration
  • Regulation of PTEN stability and activity
  • Extra-nuclear estrogen signaling
  • Negative regulation of NOTCH4 signaling
  • FLT3 Signaling
  • Regulation of localization of FOXO transcription factors
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • KEAP1-NFE2L2 pathway
  • SARS-CoV-2 targets host intracellular signalling and regulatory pathways
  • Mitochondrial unfolded protein response (UPRmt)
  • High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
  • High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
  • Mechanical load activates signaling by PIEZO1 and integrins in osteocytes
  • ATP
  • Arsenic trioxide
  • Genistein
  • Inositol 1,3,4,5-Tetrakisphosphate
  • Resveratrol
  • Archexin
  • Enzastaurin
  • Perifosine
  • N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
  • 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
  • PTEN hamartoma tumor syndrome (PHTS), including: Cowden syndrome; Bannayan-Riley-Ruvalcaba syndrome; Proteus syndrome; Proteus-like syndrome
Novel ANK2 ankyrin 2
  • Interaction between L1 and Ankyrins
  • Interaction between L1 and Ankyrins
  • COPI-mediated anterograde transport
  • Long QT syndrome, including: Romano-Ward syndrome; Jervell and Lange-Nielsen syndrome (JLNS)
Novel ANKRD2 ankyrin repeat domain 2
Novel ANTKMT adenine nucleotide translocase lysine methyltransferase
Novel ANXA3 annexin A3
  • Developmental Lineage of Pancreatic Ductal Cells
  • Fluocinolone acetonide
  • Ethanolamine
  • Difluocortolone
Novel APBB2 amyloid beta precursor protein binding family B member 2
Novel APEX1 apurinic/apyrimidinic endodeoxyribonuclease 1
  • Displacement of DNA glycosylase by APEX1
  • POLB-Dependent Long Patch Base Excision Repair
  • Resolution of AP sites via the multiple-nucleotide patch replacement pathway
  • PCNA-Dependent Long Patch Base Excision Repair
  • Abasic sugar-phosphate removal via the single-nucleotide replacement pathway
  • Resolution of Abasic Sites (AP sites)
  • Lucanthone
Novel APPL1 adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1
  • Caspase activation via Dependence Receptors in the absence of ligand
Novel APTX aprataxin
  • Ataxia with ocular apraxia (AOA), including: Ataxia telangiectasia (AT); Ataxia telangiectasia like disorder (ATLD); Ataxia oculomotor apraxia type 1 (AOA1); Ataxia oculomotor apraxia type 2 (AOA2)
  • Coenzyme Q10 deficiency
Novel ARAF A-Raf proto-oncogene, serine/threonine kinase
  • RAF activation
  • MAP2K and MAPK activation
  • Negative regulation of MAPK pathway
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF1 fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • SHOC2 M1731 mutant abolishes MRAS complex function
  • Gain-of-function MRAS complexes activate RAF signaling
  • ATP
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
Novel ARID1A AT-rich interaction domain 1A
  • RMTs methylate histone arginines
  • RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
  • Positive Regulation of CDH1 Gene Transcription
  • Regulation of MITF-M-dependent genes involved in pigmentation
  • Regulation of MITF-M-dependent genes involved in pigmentation
  • Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs)
  • Formation of the canonical BAF (cBAF) complex
  • Formation of the embryonic stem cell BAF (esBAF) complex
  • Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF)
  • Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF)
Novel ARID3A AT-rich interaction domain 3A
  • TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
Novel ARIH2 ariadne RBR E3 ubiquitin protein ligase 2
  • Antigen processing: Ubiquitination & Proteasome degradation
Novel ARL3 ARF like GTPase 3
  • Trafficking of myristoylated proteins to the cilium
  • 2-(N-morpholino)ethanesulfonic acid
  • Guanosine-5'-Diphosphate
Novel ARRB1 arrestin beta 1
  • Activated NOTCH1 Transmits Signal to the Nucleus
  • G alpha (s) signalling events
  • Lysosome Vesicle Biogenesis
  • Golgi Associated Vesicle Biogenesis
  • Thrombin signalling through proteinase activated receptors (PARs)
  • Activation of SMO
  • Activation of SMO
  • MAP2K and MAPK activation
  • Ub-specific processing proteases
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF1 fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • TGFBR3 regulates TGF-beta signaling

Page 1 out of 52 pages